BofA IG Healthcare Weekly: Vital Signs

Research evidence excerpt

BofA IG Healthcare Weekly: Vital Signs

Accessible version

BofA IG Healthcare Weekly

Vital Signs

Industry Overview

Healthcare Highlights: VTRS, GSK, JNJ, HUM, ROSW, 15 June 2026

NOVNSW, XRAY, AZN, MRK, DHR High Grade Credit

United StatesViatris issued €650 million 4.250% notes due 2033. GSK plc announced the acquisition of Healthcare

Nuvalent for $10.6 billion, with an expected close in the third quarter of this year. The deal

includes two late-stage assets, ROS1 (zidesamtinib) and ALK (neladalkib), for non-small cell Andrew Kaplan

lung cancer which are currently under U.S. FDA review for 2026 approvals. Johnson & ResearchBofAS Analyst

Johnson announced the acquisition of Firefly Bio for $1 billion, bolstering its oncology +1 646 855 8748

andrew.kaplan@bofa.com

pipeline, with an expected close later this year. Humana announced the divestment of its

minority interest in Gentiva for $900 million. The transaction is expected to close in the VritikaResearchPatniAnalyst

third quarter of this year. Roche announced a global collaboration with Nurix Therapeutics. BofAS

+1 646 855 7042

The collaboration adds to Roche’s oncology pipeline and offers potential indications in vritika.patni@bofa.com

immunology and neurology. Under the terms, Roche will pay $700 million upfront, as well

as milestones, for a total deal value of up to $2.3 billion. Novartis announced a strategic

collaboration with Orionis Biosciences to discover and design molecular glue drugs for

therapeutic targets across multiple disease areas. Novartis will pay $40 million upfront and

Stock symbols and abbreviations

milestones up to $1.4 billion. Dentsply Sirona appointed John Fortson as Chief Financial VTRS Viatris

Officer, effective July 20. Mr. Fortson most recently served as President and CFO of GSK GSK plc